CRISPR Therapeutics AG

SecurityCRSP / CRISPR Therapeutics AG
InstitutionInvesco Ltd.
Latest Disclosed Ownership64,117 shares
Latest Disclosed Value $ 3,050,045
Invesco Ltd. reports 5.46% increase in ownership of CRSP / CRISPR Therapeutics AG

On May 12, 2026 - Invesco Ltd. filed a 13F-HR form disclosing ownership of 64,117 shares of CRISPR Therapeutics AG (US:CRSP) valued at $3,050,046 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 19, 2026 disclosing 60,796 shares of CRISPR Therapeutics AG. This represents a change in shares of 5.46% during the quarter. The current value of the position is $3,651,463 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 64,117 3,321 5.46 3,050 -4.33 0.0001
2026-02-19 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 60,796 -4,531 -6.94 3,188 -24.69 0.0005
2025-11-13 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 65,327 -1,321 -1.98 4,234 30.61 0.0007
2025-08-13 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 66,648 38,691 138.39 3,242 240.80 0.0006
2025-05-12 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 27,957 -5,833 -17.26 951 -28.44 0.0002
2025-02-13 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 33,790 2,010 6.32 1,330 -10.98 0.0002
2024-11-12 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 31,780 -1,120 -3.40 1,493 -15.93 0.0003
2024-08-13 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 32,900 1,332 4.22 1,777 -17.43 0.0004
2024-05-14 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 31,568 -19,616 -38.32 2,152 -32.87 0.0005
2024-02-13 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 51,184 -84,939 -62.40 3,204 -48.14 0.0008
2023-11-13 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 136,123 2,061 1.54 6,179 -17.91 0.0017
2023-08-11 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 134,062 -3,221 -2.35 7,526 21.21 0.0020
2023-05-12 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 137,283 12,219 9.77 6,209 22.15 0.0017
2023-02-13 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 125,064 -1,083 -0.86 5,084 -38.34 0.0015
2022-11-14 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 126,147 -1,311 -1.03 8,244 6.44 0.0027
2022-08-15 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 127,458 9,335 7.90 7,745 4.45 0.0023
2022-05-16 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 118,123 26,428 28.82 7,415 6.72 0.0019
2022-02-14 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 91,695 -4,757 -4.93 6,948 -35.64 0.0017
2021-11-15 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 96,452 -31,768 -24.78 10,796 -47.99 0.0027
2021-08-17 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 128,220 10,438 8.86 20,756 44.63 0.0051
2021-05-17 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 117,782 -187,564 -61.43 14,351 -69.30 0.0038
2021-02-16 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 305,346 163,412 115.13 46,752 293.80 0.0136
2020-11-16 2020-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 141,934 -42,578 -23.08 11,872 -12.45 0.0040
2020-08-14 2020-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 184,512 -5,795 -3.05 13,560 68.01 0.0048
2020-05-15 2020-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 190,307 56,928 42.68 8,071 -0.64 0.0034
2020-02-14 2019-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 133,379 103,822 351.26 8,123 570.21 0.0025
2019-11-14 2019-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 29,557 29,557 1,212 0.0003
2018-11-14 2018-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 0 -75,075 -100.00 0 -100.00
2018-08-14 2018-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 75,075 75,075 4,411 0.0015
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.